tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
BioMarin Pharmaceutical: Strong Financial Performance and Promising Pipeline Justify Buy Rating
PremiumRatingsBioMarin Pharmaceutical: Strong Financial Performance and Promising Pipeline Justify Buy Rating
24d ago
BioMarin Pharmaceutical: Strong Financial Performance and Promising Future Drive Buy Rating
Premium
Ratings
BioMarin Pharmaceutical: Strong Financial Performance and Promising Future Drive Buy Rating
24d ago
BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results
Premium
Company Announcements
BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results
24d ago
BioMarin raises FY25 adjusted EPS view to $4.40-$4.55 from $4.20-$4.40
PremiumThe FlyBioMarin raises FY25 adjusted EPS view to $4.40-$4.55 from $4.20-$4.40
25d ago
BMRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
BMRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
27d ago
BioMarin Expands Board with New Director Appointment
Premium
Company Announcements
BioMarin Expands Board with New Director Appointment
28d ago
BioMarin price target lowered to $96 from $97 at Morgan Stanley
PremiumThe FlyBioMarin price target lowered to $96 from $97 at Morgan Stanley
1M ago
BioMarin Pharmaceutical: Undervalued Stock with Promising Growth Catalysts and Positive Outlook
Premium
Ratings
BioMarin Pharmaceutical: Undervalued Stock with Promising Growth Catalysts and Positive Outlook
1M ago
BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment
Premium
Company Announcements
BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100